US antitrust lawsuit against Dr Reddy's voluntarily dismissed

The lawsuit, filed on November 22, this year by indirect purchasers, also named Revlimid innovators Celgene and Bristol-Myers Squibb as defendants, as well as several generic pharmaceutical companies

FPJ Web DeskUpdated: Thursday, December 29, 2022, 11:43 AM IST
article-image
Image credit: Dr Reddy's (Representative)

US antitrust lawsuit against Dr Reddy's Laboratories Ltd, its US based-subsidiary Dr Reddy's Laboratories Inc, with regard to a generic of Revlimid, has been voluntarily dismissed by plaintiffs, the company said in an exchange filing today.

It is not clear whether the company settled with the plaintiffs, or the suit was withdrawn for any other reasons. All claims against the company in the litigation have been dismissed.

The lawsuit, filed on November 22, this year by indirect purchasers, also named Revlimid innovators Celgene and Bristol-Myers Squibb as defendants, as well as several generic pharmaceutical companies. The case is "voluntary dismissed" against all the defendants, the company said.

The lawsuit alleged Dr Reddy's and other companies claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Government rescues Vodafone Idea, converts dues into 35% stake

Government rescues Vodafone Idea, converts dues into 35% stake

Another blow for Indian pharma, drug linked to vision loss in US recalled

Another blow for Indian pharma, drug linked to vision loss in US recalled